Incyclix Bio Secures $11.25M Series B Extension for Ph 1/2 Trial of INX-315 in CDK4/6i-Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors August 26, 2025
ATG-022 Granted Breakthrough Therapy Designation for the Treatment of Gastric/GEJ Adenocarcinoma August 26, 2025
First Patient Dosed in Pivotal Ph 3 Trial of Cadonilimab for Perioperative Treatment of Resectable Gastric Cancer August 26, 2025
VantAI and Halda Therapeutics Forge Alliance to Discover Next-Generation RIPTAC Medicines August 26, 2025
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib August 26, 2025
N-Power Medicine Launches External Control Arm Platform to Accelerate Oncology Drug Development and Reduce Reliance on Randomization August 26, 2025
First Patient Dosed in Ph 1 inMMyCAR Study of in vivo CAR T-cell Therapy for RRMM patients August 26, 2025
First patient dosed in registrational clinical trial of mesutoclax for the treatment of BTKi-experienced mantle cell lymphoma in China August 26, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC August 26, 2025
Enrollment paused in Ph 1/2 OPAL-1 trial of intratumoral KB707 in solid tumors, prioritizing work on inhaled KB707 in NSCLC August 26, 2025
Nature Medicine Publishes Results of Ph 2 Study of Sacituzumab Tirumotecan Plus Tagitanlimab in 1L NSCLC August 26, 2025
Final Topline Survival Data from VERSATILE-002 Ph 2 Trial in 1L R/M HNSCC showing median OS of 39.3 months in patients with CPS ≥ 1 announced August 26, 2025
FDA accepted Type C meeting request for Doxorubicin Containing Novel Microneedle Array (D-MNA); SKNJCT-003 Ph 2 study randomize more than 75% of patients August 26, 2025
Premarket approval (PMA) application submitted to FDA for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer August 26, 2025
FDA clears IND application of 7MW4911 to initiate Ph 1/2 trial in patients with advanced CRC and other advanced gastrointestinal tumors August 26, 2025
European Commission Approves Tablet Formulation of BRUKINSA® for All Approved Indications August 26, 2025
